FDA finalizes a guidance outlining how generic drug developers should evaluate the adhesion performance of transdermal and topical delivery systems.
A new FDA draft guidance outlines how sponsors should develop and evaluate container closure systems and device components used with biosimilar and interchangeable biosimilar products.
FDA finalizes a guidance outlining how generic drug developers should evaluate the adhesion performance of transdermal and topical delivery systems.
A new FDA draft guidance outlines how sponsors should develop and evaluate container closure systems and device components used with biosimilar and interchangeable biosimilar products.
Sen. Ron Johnson asks to interview four former CBER officials and Anthony Fauci on the safety and efficacy of Covid vaccines.
FDA accepts for priority review a Johnson & Johnson supplemental BLA for subcutaneous Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma.
